Study Design and Oversight
ZOE-50 is an ongoing, randomized, placebo-controlled
study conducted in 18 countries in Europe,
North America, Latin America, and Asia–
Australia. It was designed to evaluate the efficacy,
immunogenicity, and safety of the HZ/su vaccine
in adults who are 50 years of age or older. The
study protocol was approved by the appropriate
independent ethics committee or institutional
review board at each study center. Written informed
consent was obtained from all participants
before study entry.
The study is being conducted in accordance
with the provisions of the Declaration of Helsinki
and the International Conference on Harmonisation–Good
Clinical Practice guidelines.
During the course of the study, potential research
compliance issues were investigated and
appropriate actions were taken when needed.
(Details are provided in the Supplementary Appendix,
available with the full text of this article
at NEJM.org.)